COLO B Coloplast A/S Class B

Coloplast launches Biatain® Silicone Fit for pressure injury prevention and wound management in the US

Coloplast launches Biatain® Silicone Fit for pressure injury prevention and wound management in the US

The company aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients.

  • “We are now introducing new innovation to the US market, aiming to grow our presence within the foam dressings segment. We have a great product in our hands, and we have invested significantly in our sales organization to reach the full potential of this launch. I am really excited to get started,” says Kimberly Ditter, Vice President of Wound & Skin Care, North America.

Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually1, while 2.5 million patients develop a pressure injury in acute care facilities each year2. Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients.

  • “Choosing the right dressing for wound treatment or pressure injury prevention should be simple and easy and give the patient a soft, secure and comfortable fit. Biatain Silicone Fit offers exactly that. It fits to the body, and it fits to the wound,” says Kimberly Ditter.



Fits to the body and fits to the wound

Biatain Silicone Fit with 3DFit Technology is designed for both pressure injury prevention and wound management. It stays securely in place during patient movement, fitting to body creases and allowing easy skin inspection as part of pressure injury prevention protocols3. It also matches the shape and depth of the wound bed up to 2 cm deep4, lowering the risk of infection and maceration for optimal wound healing conditions.

Biatain Silicone Fit comes in 12 different sizes and shapes to suit the facility’s needs. All sizes and shapes are developed and indicated for both pressure injury prevention and wound treatment to accommodate multiple purposes and a reduced number of SKUs.

Biatain Silicone Fit is available in the US as of January 2024.



Expanding Wound Care in the US

The global advanced wound dressings market is estimated at DKK 26-28 billion, with an annual estimated growth rate of 2-4%. Around 25-30% of the market is derived from the US, where products are typically used in the hospital setting.  

  1. Sen CK. Human Wound and Its Burden: Updated 2022 Compendium of Estimates. Adv Wound Care (New Rochelle). 2023 Dec;12(12):657-670. ()
  2. Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United States. Int Wound J. 2019 Jun;16(3):634-640. ()
  3. Coloplast data on file, 2022. Based on simulated use.
  4. Coloplast data on file 2023. Fit to the wound bed may vary across product design.



Contacts


Peter Mønster

Sr. Media Relations Manager, Global Communications



Aleksandra Dimovska

Sr. Director, Investor Relations

Attachments



EN
31/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H...

Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25 Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostomy Care. Q2 EBIT margin1 held steady at 27%. Reported revenue in DKK grew 5%, impacted by the Skin Care divestment. Organic growth rates by business area: Ostomy Care 4%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 10% and Interventional Urology -1%.Growth in Chronic Care was driven ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch